Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases - 1st Edition - ISBN: 9780128129227

Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases

1st Edition

Overview of Epidemiological Data on Smoking and Preclinical and Clinical Data on Nicotine

Authors: Emilija Veljkovic Wenhao Xia Blaine Phillips Ee Wong Jenny Ho Alberto Oviedo Casado Julia Hoeng Manuel Peitsch
Hardcover ISBN: 9780128129227
Imprint: Academic Press
Published Date: 15th January 2018
Page Count: 164
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases: Epidemiological Data on Smoking and Preclinical and Clinical Data on Nicotine provides a comprehensive summary of the epidemiological data on smoking and several neurological disorders, including Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Tourette’s syndrome, schizophrenia, anxiety, depression and ADHD, as well as preclinical and clinical data on the effects of nicotine. Despite the obvious and undisputed harmful nature of smoking, evidence suggests that some tobacco and tobacco smoke-derived constituents may offer neuroprotective effects, possibly in combinations, rather than individually.

This unprecedented book describes the complex relationships between smoking and neurological disease and the bioactive compounds found in tobacco. It provides a comprehensive review of nicotine and other compounds found in tobacco plant, with scientific evidence of neuroprotective and anti-inflammatory effects that may act in conjunction with nicotine to exert neuroprotective effects observed in smokers.

By presenting findings beyond harmful cigarette smoke effects, attention can be drawn to individual compounds of tobacco that may serve as inspiration for further therapy development.

Key Features

  • Presents the first comprehensive, tabulated summary of literature on the epidemiological data on smoking and neurological disease
  • Includes preclinical and clinical data on nicotine in neurological diseases and mechanisms of action of nicotine in neuroprotection
  • Features a comprehensive summary of non-nicotine smoke constituents with potentially neuroprotective and anti-inflammatory properties
  • Discusses Multiple Sclerosis, Alzheimer’s disease, Parkinson’s Disease, Schizophrenia, Depression, ADHD, Anxiety and Tourette’s Syndrome in the context of smoking and nicotine

Readership

Neuroscientists, neurobiologists, neurologists, toxicologists, pharmaceutical scientists, post-doctoral fellows, researchers, graduate students in biological and biomedical sciences

Table of Contents

Foreword

Introduction

Search Methods

  1. Parkinson’s disease
  2. -Symptoms and epidemiology of Parkinson’s disease (high level), molecular mechanisms and focusing on impact of smoking providing a comprehensive tables with clinical and nonclinical evidences of impact of nicotine

  3. Alzheimer's disease
  4. -Symptoms and epidemiology of Alzheimer’s disease (high level), molecular mechanisms and focusing on impact of smoking providing a comprehensive tables with clinical and nonclinical evidences of impact of nicotine

  5. Multiple sclerosis
  6. -Symptoms and epidemiology of multiple sclerosis, molecular mechanisms and impact of smoking and nicotine Tourette syndrome

  7. Schizophrenia
  8. -High level description of symptoms and epidemiology of the disease, some molecular mechanisms, impact of smoking with clinical evidences, impact of nicotine with clinical and non-clinical evidences

  9. Tourette syndrome
  10. -Symptoms, epidemiology and potential causes of Tourette’s syndrome (high level), focusing on impact of smoking providing a comprehensive tables with clinical and nonclinical evidences of impact of nicotine

  11. Attention Deficit Hyperactivity Disorder
  12. -Symptoms, epidemiology and potential causes of ADHD (high level), focusing on impact of smoking providing a comprehensive tables with clinical and nonclinical evidences of impact of nicotine

  13. Depression
  14. -Symptoms, epidemiology and potential causes, impact of smoking and nicotine

  15. Anxiety
  16. -Symptoms, epidemiology and potential causes, impact of smoking and nicotine

  17. Nicotine
  18.  -Impact of nicotine on cognitive functions, nicotinic acetylcholine receptors, nicotine effects on neurotransmitter systems and on cellular molecular signaling, nAChRs in mitochondria, nAChRs in neural stem cells and in microglia and transmembrane transport of nicotine

  19. Other Compounds from Tobacco with Potential Impact on Neurodegenerative Diseases
  20. -nAChRs agonists, MAO inhibitors in therapy of neurodegenerative diseases, other tobacco compounds and neuroprotection: Cotinine, Anatabine, anabasine and other tobacco alkaloids, Cembranoids, Scopoletin, Eugenol, Rutin, Ferulic acid, Chlorogenic acid, β-Carboline, Resorcinol, β-sitosterol, Quinoline, Sinapyl alcohol, Caffeic acid

  21. Research Models of Neurodegenerative Diseases: Major Considerations for Translatibility
  22.  

  23. Concluding Remarks
  24.  

Details

No. of pages:
164
Language:
English
Copyright:
© Academic Press 2018
Published:
Imprint:
Academic Press
Hardcover ISBN:
9780128129227

About the Author

Emilija  Veljkovic

Emilija Veljkovic

Dr. Veljkovic is Manager - Study Management at Phillip Morris International in Neuchatel, Switzerland. Her research group is responsible for in vivo studies designed to further characterize the exact role of the cigarette smoke in initiation and development of lung pathologies (lung cancer, COPD) and CVD. She has nine years of experience in the tobacco industry, with a focus on inhalation toxicology and modeling of smoking-related diseases (lung cancer, chronic obstructive pulmonary disease) engaging systems toxicology approaches. With a thorough understanding of nicotine-related toxicity in animal models, Dr. Veljkovic and her team have prepared a number of internal strategic documents that required an extensive literature review about effects of nicotine and non-nicotine tobacco constituents in different diseases including neurological and neurodegenerative diseases. She holds BSc, MSc and PhD degrees in molecular biology and physiology.

Affiliations and Expertise

Philip Morris International Research laboratories Singapore, Singapore

Wenhao  Xia

Wenhao Xia

Dr. Xia is Scientist - Study Management at Phillip Morris International Laboratories with experience in drug discovery for neurodegenerative diseases. He has a profound understanding of molecular mechanisms of neurodegeneration in preclinical in vivo models and holds a BSc in life sciences and a PhD in neurobiology.

Affiliations and Expertise

Philip Morris International Research laboratories Singapore, Singapore

Blaine Phillips

Blaine Phillips

Dr. Phillips is Senior Scientist - Study Management at Phillip Morris International in Singapore. His research group is focused on late-stage biological assessment of next generation reduced-harm tobacco products within the framework of the R&D department. He is an expert in inhalation toxicology and modeling of smoking-related diseases using systems toxicology approaches. He has ten years’ experience in biotechnology and the pharmaceutical industry, and a thorough understanding of nicotine-related toxicity in animal models. Dr. Phillips holds a BSc in molecular biology and a PhD in medical science.

Affiliations and Expertise

Philip Morris International Research laboratories Singapore, Singapore

Ee  Wong

Ee Wong

Dr. Wong is Senior Scientist - Study Management and has 4 years of experience in tobacco industry, focused on OECD type of toxicology studies and modeling of smoking related diseases, especially lung cancer. Ee Tsin has a solid understanding of nicotine toxicity in rat and mice in inhalation set up. Ee Tsin holds BSc in biochemistry and PhD in biology.

Affiliations and Expertise

Philip Morris International Research laboratories Singapore, Singapore

Jenny  Ho

Jenny Ho

Dr. Ho is Scientist - Study Management with expertise in bioanalytical method and a focus on detection and quantification of smoke exposure markers. Her specialities include development and validation of analytical methods for biopharmaceuticals and chemical entities, protein sequencing, nano- and bio-material production for bioapplications, and vaccine and drug delivery systems. Dr. Ho holds a BSc in chemical engineering and a PhD in biochemical engineering.

Affiliations and Expertise

Philip Morris International Research laboratories Singapore, Singapore

Alberto  Oviedo Casado

Alberto Oviedo Casado

Dr. Oviedo Casado is Supervisor - Bioscience Operations, with a focus on inhalation toxicology and modeling of smoking- and inflammation-related diseases. His group is responsible for the execution of pre-clinical studies, and he manages the scientific technique portfolio. He has an extensive understanding of nicotine and tobacco products toxicity in the context of OECD type of toxicological studies. Dr. Oviedo Casado holds a BSc in biochemistry and a PhD in cell and molecular biology.

Affiliations and Expertise

Philip Morris International Research laboratories Singapore, Singapore

Julia  Hoeng

Julia Hoeng

Dr. Hoeng is Director of Systems Biology at Phillip Morris International and program leader. She has a profound understanding of inhalation toxicology and computational modeling of smoking-related diseases, lung cancer, COPD, and CVD. Dr. Hoeng holds a BSc in biology, MSc in bioinformatics, PhD in protein crystallography, and an executive MBA.

Affiliations and Expertise

Philip Morris International, Research and Development, Neuchatel, Switzerland

Manuel  Peitsch

Manuel Peitsch

Dr. Peitsch is Chief Scientific Officer and VP of Research and Development at Philip Morris International. He has extensive experience in tobacco harm reduction, smoking-related diseases, systems biology, toxicology, bioinformatics, chemoinformatics, high-performance computing, and knowledge management. An innovation-focused results-driven biomedical research leader, Dr. Peitsch has many years of experience managing large multi-cultural teams across several countries. He holds several patents related to proteomics, genomics, and computer science and has published over 200 book chapters, technical reports, and articles in top ranking scientific journals (cited over 22000 times). He has done pioneering work in the area of molecular modeling, cell biology, computational text analytics, and systems biology/toxicology and is a founder of several initiatives, including two start-up companies, the Swiss Institute of Bioinformatics, and the [BC]2 conference (http://www.bc2.ch). He is Chairman of the Executive Board of the Swiss Institute of Bioinformatics and an active scientific advisor to several academic and commercial entities. He has also served on the Swiss National Research Council. Dr. Peitsch is a Computerworld Honors Laureate and a recipient of several awards including the New England Business and Technology Award and the United Devices Grid Visionary Award. He holds a BSc in life sciences, MSc in physical chemistry, and PhD in biochemistry. He is also Professor of Bioinformatics at the University of Basel.

Affiliations and Expertise

Philip Morris International, Research and Development, Neuchatel, Switzerland

Ratings and Reviews